基线全身代谢活性肿瘤体积联合早期代谢反应改善转移性结直肠癌预后预测
本研究在开发队列(比利时多中心试验中化疗难治性mCRC患者)和验证队列(意大利中心一线化疗联合贝伐珠单抗的mCRC患者)中,评估基线18F-FDG PET/CT全身代谢活性肿瘤体积(WB-MATV)和早期代谢反应(mR)的预后价值。结果显示WB-MATV和CONSIST法评估的早期mR是OS和PFS的独立预后因素,联合二者可改善风险分层。
要点
- 基线WB-MATV和早期mR是mCRC患者OS和PFS的独立预后生物标志物。
- CONSIST法(所有靶病灶SULmax下降≥15%)在预测结局方面最准确。
- 联合WB-MATV与早期mR可改善mCRC的风险分层。
核心结论
- 基线WB-MATV和早期mR是mCRC患者OS和PFS的强独立预后生物标志物,无论接受何种治疗。
- 联合这些生物标志物可改善mCRC的OS和PFS风险分层。
研究设计与样本
- 开发队列为2项比利时多中心前瞻性试验中接受末线多激酶抑制剂治疗的化疗难治性mCRC患者。
- 验证队列为意大利中心接受一线化疗联合贝伐珠单抗的mCRC患者。
- 基线WB-MATV定义为基线18F-FDG PET/CT上所有靶病灶代谢活性体积之和。
- 早期mR采用常规反应标准(PERCIST-30%、PERCIST-15%、EORTC)和CONSIST法(所有靶病灶SULmax下降≥15%)评估。
- 开发队列239例中192例可评估,验证队列125例中94例可评估临床因素、WB-MATV和早期mR。
主要发现
- 除PERCIST-30%外,所有反应评估方法在结局预测方面等效,CONSIST法最准确。
- 验证队列中,校正临床因素后WB-MATV对OS的HR为1.87(95%CI 1.17-2.97,P=0.005),早期mR对OS的HR为1.79(95%CI 1.08-2.95,P=0.02)。
- 验证队列中,WB-MATV对PFS的HR为1.94(95%CI 1.27-2.97,P=0.002),早期mR对PFS的HR为1.69(95%CI 1.04-2.73,P=0.03)。
关键数值与推荐
- PERCIST-30%反应阈值为30%,PERCIST-15%反应阈值为15%。
- CONSIST法定义反应为所有靶病灶SULmax下降≥15%。
临床怎么用
- 在mCRC患者中,可利用基线18F-FDG PET/CT测量WB-MATV进行预后分层。
- 治疗早期可采用CONSIST法评估代谢反应,联合WB-MATV改善风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stratification of metastatic colorectal cancer (mCRC) patients is mostly based on clinical and biologic characteristics. This study aimed to validate the prognostic value of 18F-FDG PET/CT-based biomarkers such as baseline whole-body metabolically active tumor volume (WB-MATV) and early metabolic response (mR) in mCRC. Methods: The development cohort included chemorefractory mCRC patients enrolled in 2 prospective Belgian multicenter trials evaluating last-line treatments (multikinase inhibitors). The validation cohort included mCRC patients from an Italian center treated with chemotherapy and bevacizumab as first-line. Baseline WB-MATV was defined as the sum of metabolically active volumes of all target lesions identified on the baseline 18F-FDG PET/CT. Early mR assessment was performed following usual response criteria (response threshold of 30% [PERCIST-30%], response threshold of 15% [PERCIST-15%], European Organization for Research and Treatment of Cancer) and the so-called CONSIST method, which defines response as a decrease of SULmax ≥ 15% for all target lesions. Baseline WB-MATV and early mR assessment were investigated along with usual clinical factors and correlated with overall survival (OS) and progression-free survival (PFS). Results: Clinical factors, baseline WB-MATV, and early mR were evaluable in 192 of 239 and 94 of 125 patients of the development and validation cohorts, respectively. Except for PERCIST-30%, all response methods were equivalent in terms of outcome prediction, and CONSIST was found to be the most accurate. Baseline WB-MATV and early mR using the CONSIST method were independent prognostic parameters after adjustment for clinical factors in the development and validation sets for both OS (hazard ratio [HR] WB-MATV: 1.87 [95% CI, 1.17-2.97], P = 0.005, and HR early mR: 1.79 [95% CI, 1.08-2.95], P = 0.02 for the validation set) and PFS (HR WB-MATV: 1.94 [95% CI, 1.27-2.97], P = 0.002, and HR early mR: 1.69 [95% CI, 1.04-2.73], P = 0.03 for the validation set). Conclusion: Baseline WB-MATV and early mR are strong independent prognostic biomarkers for OS and PFS in mCRC, regardless of treatment received. Therefore, combining these biomarkers improves risk stratification for OS and PFS in mCRC.
引用
- Woff E, Salvatore L, Marmorino F, et al. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer. J Nucl Med. 2021. PMID: 34326124. doi:10.2967/jnumed.120.245357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。